Bin Zhang | Gene Mutation | Best Researcher Award

Posted on by PencisLeave a Comment on Bin Zhang | Gene Mutation | Best Researcher Award

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024

Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

Posted on by PencisLeave a Comment on Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

Dr. Bijina Balakrishnan | Molecular Basis of Genetic Disease | Best Researcher Award

University of Utah | United States

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Bijina Balakrishnan embarked on her academic journey in the field of biotechnology with a Bachelor of Science degree in Biology & Chemistry from the University of Calicut, Kerala, India, in 1999. She further pursued her passion for biotechnology by obtaining a Master of Science degree in Biotechnology from Cochin University of Science and Technology, Kerala, India, in 2002. Her dedication to advancing knowledge in the field led her to pursue a Doctor of Philosophy (PhD) in Biotechnology, which she successfully completed at Cochin University of Science and Technology, Kerala, India, in 2008.

PROFESSIONAL ENDEAVORS

Balakrishnan's professional journey has been characterized by a steadfast commitment to research excellence and innovation. She has held various significant positions in esteemed academic and research institutions, including:

RESEARCH SCIENTIST University of Utah, Salt Lake City (2021 - Present)

RESEARCH ASSOCIATE University of Utah, Salt Lake City (2019 - 2021)

POST-DOCTORAL FELLOW University of Utah, Salt Lake City (2014 - 2019)

POST-DOCTORAL FELLOW Nanyang Technological University, Singapore (2008)

SENIOR RESEARCH FELLOW Kannur University, India (2007 - 2008)

GRADUATE RESEARCHER Cochin University of Science and Technology, India (2003 - 2007)

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR BASIS OF GENETICS DISEASE

Balakrishnan's contributions to the field of biotechnology are multifaceted and impactful, spanning from basic research to translational applications. Her research endeavors have primarily focused on rare metabolic disorders, with a particular emphasis on Galactosemia and dilated cardiomyopathy. Some notable contributions include:

  • Development and optimization of preclinical therapeutic interventions for Galactosemia and dilated cardiomyopathy.
  • Characterization of mouse models for Galactosemia and elucidation of disease mechanisms.
  • Design and execution of gene therapy strategies for cardiac-specific conditions.
  • Profiling small molecule modulators for novel therapeutic targets.
  • Investigation of cellular responses to viral proteins, such as the SARS-CoV-2 Spike protein, and evaluation of potential therapeutic interventions.

IMPACT AND INFLUENCE

Balakrishnan's work has made a significant impact on both the scientific community and the broader field of biotechnology. Her research findings have been presented at numerous conferences and workshops, contributing to the dissemination of knowledge and fostering collaboration among scientists. Additionally, her efforts have led to the development of novel therapeutic approaches for rare metabolic disorders, offering hope to patients and clinicians alike.

ACADEMIC CITATIONS

Balakrishnan's research contributions have been recognized through academic honors and awards, including the Best Researcher Award at the International Research Awards on Cardiology and Cardiovascular Medicine. Moreover, she has received prestigious grants and funding support from organizations such as the Galactosemia Foundation and the National Institutes of Health (NIH).

LEGACY AND FUTURE CONTRIBUTIONS

Balakrishnan's legacy in the field of biotechnology is characterized by her dedication to scientific inquiry, innovation, and translational research. As she continues her professional journey, she remains committed to advancing knowledge, developing novel therapeutic interventions, and mentoring the next generation of scientists. Her future contributions are poised to further shape the landscape of biotechnology and positively impact the lives of individuals affected by rare metabolic disorders.

NOTABLE PUBLICATIONS

Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia 2020(38)

Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors 2021(3)

AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG) 2023(3)

AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG)

Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia

Laura Warmke | Pathology | Best Researcher Award

Posted on by PencisLeave a Comment on Laura Warmke | Pathology | Best Researcher Award

Dr. Laura Warmke | Pathology | Best Researcher Award

University of Indiana School of Medicine | United States

Author Profile

Orcid ID

EARLY ACADEMIC PURSUITS:

During my undergraduate years from 2005 to 2009 at the University of Virginia, I pursued a Bachelor of Science in Chemistry with Distinction, accompanied by a Minor in Studio Art. This foundational period laid the groundwork for my multifaceted approach to learning, blending the analytical rigor of the sciences with the creative elements of studio art.

PROFESSIONAL ENDEAVORS:

In 2010, I embarked on the journey towards a Doctor of Medicine (M.D.) degree at the Virginia Commonwealth University School of Medicine in Richmond, VA. This phase of my education marked the transition from theoretical knowledge to the practical application of medical expertise, fostering my commitment to the field of pathology.

CONTRIBUTIONS AND RESEARCH FOCUS ON PATHOLOGY:

Throughout my residency at Virginia Commonwealth University Health System (2014-2017), I actively engaged in the field of Anatomic Pathology/Clinical Pathology (AP/CP), developing a keen interest in bone and soft tissue pathology. This interest led me to pursue specialized training, culminating in my Selective Bone & Soft Tissue Pathology Fellowship at The University of Texas MD Anderson Cancer Center in Houston, TX (2019-2020).

IMPACT AND INFLUENCE:

My role as the AP/CP Pathology Chief Resident at Virginia Commonwealth University Health System (2017-2018) allowed me to contribute significantly to the department's operations. I played a pivotal role in bridging clinical and anatomical aspects, fostering a comprehensive understanding of pathology.

ACADEMIC CITES:

In 2018, I achieved board certification in Anatomic Pathology/Clinical Pathology (AP/CP) from the American Board of Pathology, affirming my proficiency and dedication to maintaining the highest standards in the field.

LEGACY AND FUTURE CONTRIBUTIONS:

Since 2020, I have served as an Assistant Professor of Clinical Pathology & Laboratory Medicine at Indiana University School of Medicine. In this capacity, I continue to impart knowledge, mentor future pathologists, and contribute to the advancement of pathology through my clinical work and research endeavors.

HIGHLIGHTS:

My commitment to excellence is underscored by my continuous pursuit of knowledge and certifications, including my current Indiana Medical License (expiring 10/31/2025) and my status as a Basic Life Support (BLS) Provider certified by the American Heart Association.

FUTURE CONTRIBUTIONS:

Looking ahead, I am dedicated to furthering research, education, and patient care in the realm of pathology. I aspire to make enduring contributions to the field, leaving a lasting legacy through my dedication to excellence, mentorship, and continued pursuit of knowledge.

Notable publications:

Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma 2022(1)

“PRRX1-rearranged mesenchymal tumors”: expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature 2022(3)

NR1D1::MAML1 epithelioid and spindle cell sarcoma mimicking pseudomyogenic hemangioendothelioma in core biopsy: A case report and review of the literature 2023(1)